SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A.

Their core work

SEA4US is a Portuguese marine biotechnology SME based in Sagres, specializing in discovering and developing bioactive compounds from marine organisms — particularly algae — for pharmaceutical and nutraceutical applications. Their work spans the full pipeline from marine bioprospecting to functional product development, with a strong focus on pain management and inflammatory conditions. They bridge marine biology with human health, turning ocean-sourced molecules into potential therapeutics and functional foods.

What they specialise in

How they've shifted over time

SEA4US started with broader marine bioprospecting — participating in the Ocean Medicines project (2015-2019) and then coordinating Sea4Pain (2018) to develop marine-derived analgesics. Their most recent and largest project, Algae4IBD (2021-2026), shows a clear narrowing toward algae-specific biotechnology applied to gut health, functional foods, and inflammatory conditions. The trajectory is from general marine pharmacology toward targeted algae-based therapeutics and nutraceuticals.

SEA4US is moving from exploratory marine compound discovery toward applied algae biotechnology for gut health and food products — expect them to seek partners in clinical nutrition, IBD research, and algae cultivation scale-up.

How they like to work

SEA4US has coordinated one project (Sea4Pain, an SME-1 feasibility study) and participated in two larger consortia, suggesting they are comfortable both leading focused SME-stage work and contributing specialist marine biotech expertise to bigger teams. With 33 unique partners across 15 countries from just 3 projects, they are well-networked for their size. Their participation in diverse funding schemes (MSCA-RISE, SME-1, RIA) shows adaptability to different consortium structures.

Despite being a small company with only 3 H2020 projects, SEA4US has built a remarkably wide network of 33 partners across 15 countries, driven largely by participation in international research consortia like MSCA-RISE exchanges. Their network spans well beyond Southern Europe into a truly pan-European reach.

What sets them apart

SEA4US operates from Sagres — at the southwestern tip of Europe where the Atlantic meets some of the continent's richest marine biodiversity. This geographic advantage, combined with their specific focus on translating marine organisms into health products, gives them a rare position: a company that can go from ocean sample collection to bioactive compound development under one roof. For consortium builders, they offer genuine marine bioprospecting capability paired with pharmaceutical development ambition, which is uncommon among European SMEs.

Highlights from their portfolio

• Algae4IBD
  Their largest project by far (EUR 408K), running until 2026, and representing their strategic pivot toward algae-based therapeutics for inflammatory bowel disease — a growing market.
• Sea4Pain
  Their only coordinator role and an SME Phase 1 project, demonstrating entrepreneurial initiative in developing marine-derived analgesics as a commercial product.